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Summary 
Lymphocyte glucocorticoid receptor binding parameters were studied in 15 severely depressed patients 
during depression and after clinical recovery, and in 15 healthy controls. There was no difference in 
glucocorticoid receptor number or affinity between depressed patients and recovered or control subjects. 
Afternoon ACTH and cortisol concentrations did not differ significantly between the three groups. No 
relationship could be established between glucocorticoid receptor binding and antidepressant medication. 
These data support the view of an impaired ligand-induced plasticity of glucocorticoid receptor regulation 
rather than the hypothesis of decreased glucocorticoid receptor numbers during depression. 
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Introduction 
Abnormalities of hypothalamic-pituitary-adre- 
nal (HPA) system integrity linked to depression 
include 24-h hypersecretion of cortisol during de- 
pressive episodes (Linkowski et al., 1985, 1987) 
and reduced suppression of cortisol by dexa- 
methasone (Carroll et al., 1968). An escape of 
plasma adrenocorticotropic hormone (ACTH) 
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(Fang et al., 1981) and P-endorphin (Matthews et 
al., 1986; Rupprecht et al., 1988) from dexametha- 
sone suppression in endogenously depressed pa- 
tients provided further evidence for a subtle de- 
rangement of the feedback regulation of the HPA 
system during depression. Moreover, reports of an 
inadequate suppressibility of prolactin (Meltzer et 
al., 1982; Rupprecht et al., 1987) and thyroid- 
stimulating hormone (TSH) (Rupprecht et al., 
1989) following glucocorticoid administration in 
depression have supported the idea that the de- 
rangement of the glucocorticoid-mediated nega- 
tive feedback is not restricted to the HPA system, 
but also involves a variety of neuroendocrine sys- 
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terns. These neuroendocrine abnormalities seem to 
be state-dependent since the hypercortisolemia 
(Linkowski et al., 1987) and the disturbed re- 
sponse to dexamethasone (Rupprecht et al., 1989) 
revert to normal values after clinical recovery. 
Several authors have investigated lymphocyte 
glucocorticoid receptors (GR) in depression. The 
results of these studies differed quite considerably. 
Some reports noted lower GR sites per cell in 
depressed patients (Gormley et al., 1985; Whalley 
et al., 1986) while others found a reduced down- 
regulation of GR concentrations only in dexa- 
methasone suppression test (DST) non-suppres- 
sors (Lowy et al., 1988) or could not detect dif- 
ferences between depressed patients and controls 
or between DST non-suppressors and suppressors 
(Schlechte and Sherman, 1985). In addition, nor- 
mal GR values have been reported in patients 
after recovery from major depressicn when com- 
pared with healthy controls (Hunter et al.. 1988). 
As no data are available on GR binding param- 
eters during depression and after recovery in the 
same subjects. a follow-up study was undertaken 
to study GR with regard to antidepressant treat- 
ment. 
Subjects and methods 
Subjects 
Five male and 10 female subjects with unipolar 
major depressive disorder or bipolar depression 
aged between 18 and 66 years (mean k SD 48.2 of- 
14.8 years) with a mean ( k SD) body weight of 
72.5 i 13.3 kg and three male and 12 female 
healthy controls aged between 33 and 57 years 
(mean k SD 47.3 _t 7.4 years) with a mean (+ SD) 
body weight of 68.4 + 10.2 kg were studied. All 
subjects were carefully screened for medical illness 
that might influence pituitary-adrenal function by 
medical history, physical examination and routine 
laboratory tests. Six female depressed patients and 
five female controls were tested during the mid- 
luteal phase of the cycle; the other females were 
postmenopausal. 
DSM-IIIR (American Psychiatric Association 
1987) diagnoses were made on all patients by the 
TABLE 1 
DEMOGRAPHIC DATA. ANTIDEPRESSANTS PRIOR TO THE WASHOUT PERIOD AND DIAGNOSTIC DESCRIPTION 
OF THE DEPRESSED PATIENTS 
Patient Age 
(years)/sex 
I U/F 
2 66/F 
3 61/F 
4 64/F 
5 39/F 
6 60/M 
7 60/M 
8 34/F 
9 49/M 
10 54/F 
11 55/F 
12 26/F 
13 60/M 
14 18/F 
15 53/M 
DSM-IIIR 21-HRSD Drug-free period Treatment before Depressive 
depressed (days) drug-free period episodes 
- 
bipolar disorder, depressed 
MDD. recurrent, with melancholia 
MDD, recurrent. with melanchoha. 
mood-congruent psychotic 
MDD. recurrent. with melancholia 
MDD, recurrent 
MDD, recurrent, with melanchoha 
MDD, recurrent, with melancholia 
MDD. recurrent, with melancholia 
MDD, single episode 
bipolar disorder, depressed 
MDD, recurrent, with melancholia 
MDD, single episode with 
melancholia 
bipolar disorder. depressed 
MDD. single episode 
MDD. recurrent 
33 > 28 3 
36 > 28 7 
2x ) 28 3 
28 ) 28 4 
25 7 amitryptiline 100 mg 3 
24 5 amitryptiline 100 mg 3 
28 5 maprotiline 150 mg 3 
28 4 maprotiline 100 mg 3 
21 7 maprotiline 100 mg 1 
33 > 28 6 
26 5 maprotiline 150 mg 2 
26 4 amitryptiline 75 mg 1 
30 4 clomipramlne 150 mg 6 
26 > 28 1 
26 > 21 2 
MDD, major depressive disorder. 
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TABLE 2 
MEDICATION AND CLINICAL DATA OF THE RE- 
COVERED PATIENTS 
Patient 21-HRSD Treatment after Treatment 
recovered recovery (days) 
1 10 amitryptiline 
2 10 nortryptiline 
3 9 clomipramine 
4 1 lithium 
5 2 amitryptiline 
6 1 amitryptiline 
7 9 amitryptiline 
8 10 clomipramine 
9 4 clomipramine 
10 1 amitryptiline 
11 2 viloxazine 
12 6 amitryptiline 
13 2 amitryptiline 
14 4 amitryptiline 
15 5 tranylcypromine 
1OOmg 75 
480 mg 28 
1OOmg 24 
600mg 125 
200mg 30 
150 mg 30 
175 mg 90 
75 mg 89 
75 mg 31 
75 mg 28 
400mg 56 
225 mg 29 
175 mg 46 
175 mg 28 
20 mg 30 
consensus of two psychiatrists. Severity of depres- 
sion was assessed by the 21-item Hamilton Rating 
Scale for Depression (21-HRSD) and the 17-item 
HRSD (Hamilton, 1960). The mean (*SD) 21- 
item HRSD score of the patients was 26.9 & 4.8 
(range 18-36) during depression and 5.3 f 3.5 
(range l-10) after recovery. The mean (*SD) 
17-item HRSD score was 18.3 f 4.2 (range 13-27) 
during depression and 3.5 + 2.7 (range l-9) after 
recovery (Tables 1 and 2). Controls had no history 
of psychiatric disorder and were medication-free 
for at least 4 weeks. 
For determination of GR binding characteris- 
tics and hormone data, 50 ml blood was collected 
at 4 p.m. into prechilled plastic tubes containing 
EDTA. GR pharmacological characteristics were 
determined as described in detail elsewhere (Rup- 
precht et al., 1990). 
A mononuclear cell fraction was prepared by 
sodium metrizoate-Ficoll density gradient centri- 
fugation (Boyum, 1968). Cells were washed twice 
in phosphate-buffered saline (PBS) for 10 min, 
incubated for 60 n-tin at 37O C to allow sufficient 
dissociation of endogenous hormone, and then 
washed again. The final concentration of cells was 
determined using a Coulter counter (Model S5, 
Coulter Electronics Ltd, U.K.). Viability of cells 
exceeded 95%, as judged from their ability to 
exclude trypan blue. Contamination by erythro- 
cytes was less than lo%, contamination by 
granulocytes and monocytes was less than 8%. 
Binding experiments were carried out at 37 O C in 
plastic microtiter plates in a total volume of 0.25 
ml. Non-specific binding was determined with un- 
labeled dexamethasone (final concentration 10 
PM) added immediately prior to the addition of 
[3H]dexamethasone (specific activity 84 Ci/mmol). 
Saturation experiments were performed on each 
blood sample using increasing concentrations of 
[3H]dexamethasone from 1 to 40 nM. Saturation 
experiments were performed at equilibrium after a 
90-min incubation period. After incubation bound 
ligand was separated from free ligand by rapid 
filtration through Scatron filters with a Titertek 
cell harvester (Scatron, U.K.) by washing with 
PBS (pH 7.4) at room temperature. The filters 
were transferred into plastic vials, 5 ml of a 
toluene-based scintillation cocktail was added and 
samples were monitored for tritium in a Beckman 
LS 1801 counter at about 54% efficiency. All 
samples were assayed in triplicate with a variation 
within a single experiment of less than 7%. The 
number of sites per cell and dissociation constants 
were estimated by computer-assisted Scatchard 
analysis. ACTH was measured by an im- 
munoradiometric assay supplied by the Nichols 
Institute (San Juan Capistrano, CA, U.S.A.), which 
does not require extraction procedures (Raff and 
Findling, 1989). A soluble sandwich complex is 
formed by a ‘251-labeled monoclonal antibody di- 
rected against N-terminal ACTH and a biotin- 
coupled polyclonal antibody against C-terminal 
ACTH. The sandwich complexes are bound by 
adding avidin-coated plastic bead. Unbound com- 
ponents are washed away and the radioactivity 
bound to the solid phase is monitored in a y 
counter. The lower detection limit was 1.5 pmol/l, 
and the intra- and interassay coefficients of varia- 
tion were 3% and 6.8%, respectively. Values below 
the detection limit were recorded as 1.5 pmol/l. 
Cortisol was measured by a direct radioim- 
munoassay (Stalla et al., 1981). The lower detec- 
tion limit was 25 nmol/l, and the intra- and 
interassay coefficients of variation were 5% and 
9%, respectively. 
As receptor and hormone data were normally 
distributed, differences between patients and con- 
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TABLE 3 
MEAN + SD GR SITES PER CELL AND K, VALUES OF 
PATIENTS DURING DEPRESSION (n = 15) AND AFTER 
RECOVERY (n =15). AND OF HEALTHY CONTROLS 
(n =15) 
Depressed 
Recovered 
Controls 
CR sites per cell K, (nM) 
(mean k SD) (mean f SD) 
3297k1154 15.3 f 3.9 
3287+_1302 11.9f5.8 
3421* 838 13.3 f 5.6 
trols were analyzed using one-way analysis of vari- 
ance (ANOVA) followed by post hoc comparisons 
with Student’s t-test. Comparisons between de- 
pressed and recovered subjects were made by the 
f-test for paired samples. Correlation data were 
obtained by Pearson’s product moment correla- 
tion. All significance levels are two-tailed. 
Results 
The number of GR sites per cell and the dis- 
sociation constants are given in Table 3 for the 
depressed and recovered subject and for the 
healthy controls. Neither GR number nor affinity 
showed any difference between the groups studied. 
There was no relationship between the length of 
the medication-free interval, the duration of the 
current episode, the duration of treatment, the 
type of antidepressant, the number of previous 
depressive episodes, age, body weight, severity of 
depression and glucocorticoid receptor number or 
affinity. 4 p.m. ACTH or cortisol concentrations 
did not differ between the groups studied (Table 
4) and were not related significantly to any of the 
clinical variables. 
TABLE 4 
Mean+SD ACTH and cortisol levels of patients during de- 
pression (n = 15) and after recovery (n =15), and of healthy 
controls (n = 15) 
ACTH (pmol/l) 
(mean +_ SD) 
Cortisol (nmol/l) 
(mean f SD) 
Depressed 4.051.4 257.1 f 120.3 
Recovered 4.651.9 194.3 + 17.9 
Controls 3.6 + 1.2 218.0 + 77.5 
Discussion 
Our study of GR binding characteristics did 
not reveal any difference between depressed, re- 
covered, and control subjects. These findings con- 
firm previous investigations (Schlechte and Sher- 
man, 1985) and suggest that the glucocorticoid 
receptor is not down-regulated by hypercortisol- 
emia in depression. However, others have reported 
lower glucocorticoid binding sites in depression 
(Gormley et al., 1985; Whalley et al., 1986). We 
did not find a significant elevation of 4 p.m. 
baseline cortisol during the depressive episode, 
however, this does not exclude hypercortisolemia 
in our study, since it was only a single point 
measurement and the HPA axis is relatively 
quiescent at this time (Amsterdam et al., 1987). 
However, the depressed patients showed an at- 
tenuated suppression of ACTH by dexamethasone 
even after metyrapone pretreatment (Rupprecht et 
al., 1991) which points to a derangement of the 
feedback mechanism of the HPA system in the 
majority of these subjects. 
Only one study has examined glucocorticoid 
binding in patients recovered from major depres- 
sion (Hunter et al., 1988) and found normal values 
when compared with controls, which is in accor- 
dance with our results. However, this investigation 
did not compare the recovered with the depressed 
state. We could not detect any differences in 
baseline GR binding between depressed and re- 
covered subjects. However, a decreased plasticity 
of GR regulation (e.g., up- and down-regulation) 
following major shifts of endogenous hormone 
values in the face of unchanged baseline GR num- 
bers has recently been noted in depressed patients 
(Rupprecht et al., 1991). These data indicate a 
deficiency in GR autoregulation rather than a 
change in absolute receptor number during de- 
pression, which cannot be detected by baseline 
measurements but only in regulation studies. 
We could not establish a relationship between 
antidepressant medication and GR binding. This 
is in accordance with the results of Hunter et al. 
(1988) but contrasts with the report of Whalley et 
al. (1986) who noted higher GR sites in depressed 
patients pretreated with antidepressants. However, 
the glucocorticoid receptor is regulated in a more 
differentiated manner in the hippocampus, where 
35 
it responds to even slight changes in endogenous 
hormone levels, than in peripheral tissues (Mc- 
Ewen et al., 1987). Of particular interest in this 
context are recent observations that antide- 
pressants might cause an increase in GR im- 
munoreactivity in the locus coeruleus of rats 
(Kitayama et al., 1988) and an increase in GR 
mRNA in primary neuronal cultures (Pepin et al., 
1989). To determine the validity of these findings 
and whether the increase in GR density might be 
one mechanism of action of antidepressant drugs 
should be a matter of future studies in molecular 
neuroendocrinology. 
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